Concepedia

Author

Sirisha L. Mushti

Center for Drug Evaluation and ResearchORCID

Also Known As

Mushti, Sirisha, Sirisha L Mushti, Sirisha L. Mushti, Sirisha Mushti

35

Publications

1.5K

Citations

13

H-Index

17

Concepts

All Affiliations

Center for Drug Evaluation and ResearchUnited States Food and Drug AdministrationEastern Virginia Medical School
SL

About

Sirisha L. Mushti is an author at Center for Drug Evaluation and Research specializing in medicine, radiation oncology, and immunology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

241

2

Immunology

2

2

203

3

Arts

1

1

38

4

Head And Neck Surgery

1

1

38

5

Health Informatics

1

1

38

Sirisha L. Mushti

×

12

Publications

1.4K

Citations

12

H-Index

YearCitations

FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy

Dickran Kazandjian, Daniel L. Suzman, Gideon M. Blumenthal,

The Oncologist

2016

473

U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab

Maitreyee Hazarika, Meredith K. Chuk, Marc R. Theoret,

Clinical Cancer Research

2017

181

Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis

Julia A. Beaver, Maitreyee Hazarika, Flora Mulkey,

The Lancet Oncology

2018

172

FDA Approval Summary: Pembrolizumab for the First-line Treatment of Patients with MSI-H/dMMR Advanced Unresectable or Metastatic Colorectal Carcinoma

Sandra J. Casak, Leigh Marcus, Lola A. Fashoyin‐Aje,

Clinical Cancer Research

2021

167

FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with <i>RET</i> Gene Mutations or Fusions

Diana Bradford, Erin Larkins, Sirisha L. Mushti,

Clinical Cancer Research

2020

161

FDA Approval of Nivolumab for the First-Line Treatment of Patients with BRAFV600 Wild-Type Unresectable or Metastatic Melanoma

Julia A. Beaver, Marc R. Theoret, Sirisha L. Mushti,

Clinical Cancer Research

2017

57

Quality of Internet information in pediatric otolaryngology: A comparison of three most referenced websites

Peter G. Volsky, Cristina Baldassari, Sirisha L. Mushti,

International Journal of Pediatric Otorhinolaryngology

2012

38

Correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer: an FDA pooled analysis

Bernardo H. L. Goulart, Sirisha L. Mushti, Somak Chatterjee,

The Lancet Oncology

2024

31

Analysis of Vascular Closure Devices After Transbrachial Artery Access

Aleem K. Mirza, Samuel Steerman, Sadaf S. Ahanchi,

Vascular and Endovascular Surgery

2014

25

FDA Approval Summary: Futibatinib for Unresectable Advanced or Metastatic, Chemotherapy Refractory Intrahepatic Cholangiocarcinoma with FGFR2 Fusions or Other Rearrangements

Shruti U. Gandhy, Sandra J. Casak, Sirisha L. Mushti,

Clinical Cancer Research

2023

18

Page 1